The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.

Bavarian's JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and ...

African health-care workers fighting the rapid spread of a virulent mpox strain will learn how to effectively scratch under ...

Several hundred high-risk individuals were inoculated in Rwanda. Meanwhile, the Africa Centres for Disease Control and Prevention warned that the outbreak in Africa is still not under control, with ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

COPENHAGEN, Denmark I 19, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for ...

The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial ...